30-Jan-2026
Download PDF
Strides Pharma
Strides continues to deliver exceptional performance with highest ever quarterly EBITDA of Rs.2 359 million in Q3 FY26
Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.
For grievances: [email protected]
Ask Value Research 
Widely read:
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
